Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JENNIFER C CATHER

Allopathic & Osteopathic Physicians Dermatology

NPI
1154366417
CMS profile
187783
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$238,756.50

283 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 6; records 51–100 of 283 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JENNIFER C CATHER

NPI 1154366417 · CMS profile ID 187783

Allopathic & Osteopathic Physicians / Dermatology

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 6; records 51–100 of 283 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1154366417?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JENNIFER C CATHER, NPI 1154366417, CMS profile ID 187783. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 283 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1154366417?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JENNIFER C CATHER, NPI 1154366417, CMS profile ID 187783. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 283 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1154366417?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JENNIFER C CATHER, NPI 1154366417, CMS profile ID 187783, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 283 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1154366417?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

283 matching records · $238,756.50 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 283 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 283.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $186.1010/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996374725 CMS
AbbVie Inc. $171.1010/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996374727 CMS
Arcutis Biotherapeutics, Inc. $7.4210/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044742063 CMS
Dermavant Sciences, Inc. $22.3610/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991168087 CMS
Galderma Laboratories, L.P. $9.1810/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059685725 CMS
AbbVie Inc. $28.2610/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996374717 CMS
E.R. Squibb & Sons, L.L.C. $137.3010/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015772649 CMS
Novartis Pharmaceuticals Corporation $19.5110/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991704607 CMS
AbbVie Inc. $3,750.0010/17/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996374715 CMS
AbbVie Inc. $108.5610/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996374713 CMS
Arcutis Biotherapeutics, Inc. $6.0510/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044742035 CMS
AbbVie Inc. $20.5010/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996374711 CMS
Arcutis Biotherapeutics, Inc. $3,375.0010/05/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044741837 CMS
Arcutis Biotherapeutics, Inc. $3,375.0010/05/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044742149 CMS
Dermavant Sciences, Inc. $7.9110/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991168083 CMS
Lilly USA, LLC $8,000.0009/28/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031622425 CMS
Arcutis Biotherapeutics, Inc. $13.8909/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044742087 CMS
Arcutis Biotherapeutics, Inc. $107.0309/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044742159 CMS
Janssen Biotech, Inc. $29.7909/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988402843 CMS
AbbVie Inc. $22.1909/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996374709 CMS
Arcutis Biotherapeutics, Inc. $7.0109/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044742075 CMS
Lilly USA, LLC $9.1809/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061274949 CMS
Lilly USA, LLC $34.9109/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061274951 CMS
Lilly USA, LLC $39.9009/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061275085 CMS
Lilly USA, LLC $11.0409/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061275423 CMS
Lilly USA, LLC $36.6409/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061275571 CMS
Lilly USA, LLC $9.1809/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061275573 CMS
Lilly USA, LLC $6.8009/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061275731 CMS
AbbVie Inc. $18.9209/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996374707 CMS
Dermavant Sciences, Inc. $13.0409/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991168079 CMS
AbbVie Inc. $2,250.0009/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996374705 CMS
Dermavant Sciences, Inc. $464.8109/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991168059 CMS
Dermavant Sciences, Inc. $224.3809/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991168063 CMS
Dermavant Sciences, Inc. $36.5209/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991168067 CMS
Dermavant Sciences, Inc. $21.7409/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991168071 CMS
Dermavant Sciences, Inc. $32.6109/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991168075 CMS
Dermavant Sciences, Inc. $5,900.0009/15/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991168051 CMS
Dermavant Sciences, Inc. $58.0309/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991168055 CMS
Novartis Pharmaceuticals Corporation $0.0609/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991704599 CMS
Novartis Pharmaceuticals Corporation $22.0409/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991704603 CMS
Janssen Biotech, Inc. $5.7609/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988402833 CMS
PFIZER INC. $1,950.0009/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049297781 CMS
Janssen Biotech, Inc. $2.7008/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988402823 CMS
Dermavant Sciences, Inc. $5.4408/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991168047 CMS
Arcutis Biotherapeutics, Inc. $7.0008/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044742099 CMS
Novartis Pharmaceuticals Corporation $20.0708/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991704595 CMS
Janssen Biotech, Inc. $3.7608/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988402813 CMS
Lilly USA, LLC $26.6508/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031622447 CMS
Janssen Biotech, Inc. $20.8808/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988402853 CMS
Lilly USA, LLC $2,000.0008/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031707071 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $246,863.56 328
PY2020 $98,483.78 104
PY2021 $112,084.94 122
PY2022 $174,682.60 247
PY2023 $238,756.50 283
PY2024 $241,107.91 296
PY2025 $173,948.04 230

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $634,089.65 90
PY2024 Recipient $114.46 1
PY2024 Principal investigator $702,054.41 106
PY2023 Principal investigator $272,599.83 59
PY2022 Recipient $5,914.97 2
PY2022 Principal investigator $260,268.28 69
PY2021 Recipient $0.68 1
PY2021 Principal investigator $457,314.06 62
PY2020 Recipient $4,878.46 8
PY2020 Principal investigator $448,698.02 68
PY2019 Recipient $35,068.82 10
PY2019 Principal investigator $825,918.88 53

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

90 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,529.40 12/31/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202533375
Principal investigator 1 Janssen Research & Development, LLC $5,776.00 12/25/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES, PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175410560
Principal investigator 1 SANOFI US SERVICES INC. $4,926.00 12/22/2025 Non-covered Recipient Entity
Modern Research Associates Plc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226133282
Principal investigator 1 Janssen Research & Development, LLC $3,213.00 12/19/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES, PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175410553
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,138.20 12/01/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLL
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289097
Principal investigator 1 PFIZER INC. $4,421.40 11/25/2025 Non-covered Recipient Entity
Modern Research Associates PLLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228729989
Principal investigator 1 SANOFI US SERVICES INC. $3,813.00 11/17/2025 Non-covered Recipient Entity
Modern Research Associates Plc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226133268
Principal investigator 1 ABBVIE INC. $18,297.00 11/12/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202523849
Principal investigator 1 ABBVIE INC. $3,523.75 11/05/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202522017
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,538.90 11/05/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLL
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223288059
Principal investigator 1 ABBVIE INC. $3,672.00 11/04/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202520457
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $52.00 10/22/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLL
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287319
Principal investigator 1 SANOFI US SERVICES INC. $2,226.00 10/14/2025 Non-covered Recipient Entity
Modern Research Associates Plc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226133266
Principal investigator 1 ABBVIE INC. $1,572.50 10/09/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202515235
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $24,126.70 10/01/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLL
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286115
Principal investigator 1 Janssen Research & Development, LLC $1,681.00 09/29/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES, PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175410545
Principal investigator 1 Janssen Research & Development, LLC $5,933.00 09/29/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES, PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175410564
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,642.75 09/17/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223285618
Principal investigator 1 SANOFI US SERVICES INC. $13,699.00 09/15/2025 Non-covered Recipient Entity
Modern Research Associates Plc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226133245
Principal investigator 1 Janssen Research & Development, LLC $8,596.00 09/08/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES, PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175410510
Principal investigator 1 ABBVIE INC. $1,572.50 09/04/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202509044
Principal investigator 1 ABBVIE INC. $3,373.01 09/03/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202507571
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,436.90 09/03/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284899
Principal investigator 1 Janssen Research & Development, LLC $14,297.00 08/13/2025 Non-covered Recipient Entity
Modern Rsrch Associates Pllc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175279071
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,457.90 08/13/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223284217
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,246.00 08/13/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223284229
Principal investigator 1 Janssen Research & Development, LLC $4,176.00 08/01/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES, PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175410498
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,960.80 08/01/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283387
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,727.70 08/01/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283389
Principal investigator 1 SANOFI US SERVICES INC. $5,004.00 07/14/2025 Non-covered Recipient Entity
Modern Research Associates Plc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226133227
Principal investigator 1 PFIZER INC. $1,530.30 07/11/2025 Non-covered Recipient Entity
Modern Research Associates PLLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228771593
Principal investigator 1 ABBVIE INC. $1,450.00 07/08/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202497260
Principal investigator 1 ABBVIE INC. $1,669.63 07/02/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202495337
Principal investigator 1 ABBVIE INC. $6,898.00 07/02/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202495339
Principal investigator 1 Janssen Research & Development, LLC $2,649.00 06/27/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES, PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175410521
Principal investigator 1 PFIZER INC. $1,530.30 06/26/2025 Non-covered Recipient Entity
Modern Research Associates PLLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228791246
Principal investigator 1 Eli Lilly and Company $3,520.00 06/17/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187885020
Principal investigator 1 SANOFI US SERVICES INC. $6,942.00 06/16/2025 Non-covered Recipient Entity
Modern Research Associates Plc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226133206
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,555.00 06/11/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223281088
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $20,582.90 06/06/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223280946
Principal investigator 1 ABBVIE INC. $1,450.00 06/03/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202487829
Principal investigator 1 ABBVIE INC. $8,196.00 06/03/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202487915
Principal investigator 1 Janssen Research & Development, LLC $2,649.00 05/26/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES, PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175410533
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,712.40 05/21/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280066
Principal investigator 1 SANOFI US SERVICES INC. $2,238.00 05/19/2025 Non-covered Recipient Entity
Modern Research Associates Plc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226133214
Principal investigator 1 ABBVIE INC. $6,955.00 05/07/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202483797
Principal investigator 1 ABBVIE INC. $1,752.25 05/07/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202483799
Principal investigator 1 ABBVIE INC. $1,703.38 05/07/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202483925
Principal investigator 1 PFIZER INC. $2,412.60 05/06/2025 Non-covered Recipient Entity
Modern Research Associates PLLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228720477
Principal investigator 1 Janssen Research & Development, LLC $3,021.00 04/28/2025 Non-covered Recipient Entity
Modern Rsrch Associates Pllc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175278308
Principal investigator 1 Janssen Research & Development, LLC $2,310.00 04/28/2025 Non-covered Recipient Entity
Modern Rsrch Associates Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175278397
Principal investigator 1 Janssen Research & Development, LLC $2,310.00 04/28/2025 Non-covered Recipient Entity
Modern Rsrch Associates Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175279877
Principal investigator 1 Janssen Research & Development, LLC $6,932.00 04/25/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES, PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175410538
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,526.80 04/11/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278044
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,067.10 04/09/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223277730
Principal investigator 1 SANOFI US SERVICES INC. $26,806.80 04/07/2025 Non-covered Recipient Entity
Modern Research Associates Plc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226133184
Principal investigator 1 ABBVIE INC. $675.25 04/03/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202470109
Principal investigator 1 ABBVIE INC. $2,017.25 04/03/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202470114
Principal investigator 1 ABBVIE INC. $11,647.00 04/03/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202470118
Principal investigator 1 ABBVIE INC. $1,636.20 04/03/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1202470122
Principal investigator 1 SANOFI US SERVICES INC. $6,867.30 04/02/2025 Non-covered Recipient Entity
Modern Research Associates Plc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226133160
Principal investigator 1 Janssen Research & Development, LLC $3,466.00 03/24/2025 Non-covered Recipient Entity
Modern Rsrch Associates Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175279022
Principal investigator 1 SANOFI US SERVICES INC. $3,654.90 03/24/2025 Non-covered Recipient Entity
Modern Research Associates Plc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226133152
Principal investigator 1 SANOFI US SERVICES INC. $10,824.20 03/24/2025 Non-covered Recipient Entity
Modern Research Associates Plc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226133168
Principal investigator 1 Janssen Research & Development, LLC $1,634.00 03/21/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES, PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175410515
Principal investigator 1 Eli Lilly and Company $78,268.00 03/11/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187887126
Principal investigator 1 Eli Lilly and Company $1,197.02 03/10/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187884278
Principal investigator 1 ABBVIE INC. $3,070.00 03/07/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202461699
Principal investigator 1 ABBVIE INC. $252.00 03/07/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202461808
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,162.80 03/07/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223276135
Principal investigator 1 ABBVIE INC. $5,146.00 03/06/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202458509
Principal investigator 1 Eli Lilly and Company $4,641.00 03/06/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187886576
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,723.20 03/05/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223276031
Principal investigator 1 Janssen Research & Development, LLC $3,860.00 03/03/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES, PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175410504
Principal investigator 1 Janssen Research & Development, LLC $1,228.00 02/27/2025 Non-covered Recipient Entity
Modern Rsrch Associates Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175279477
Principal investigator 1 Janssen Research & Development, LLC $3,466.00 02/27/2025 Non-covered Recipient Entity
Modern Rsrch Associates Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175280794
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $18,587.40 02/26/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223275657
Principal investigator 1 Eli Lilly and Company $4,695.30 02/25/2025 Covered Recipient Teaching Hospital
U OF U HOSPITALS & CLINICS
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187875323
Principal investigator 1 Janssen Research & Development, LLC $7,711.00 02/07/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES, PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175410526
Principal investigator 1 ABBVIE INC. $1,871.00 02/06/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202448370
Principal investigator 1 ABBVIE INC. $3,879.00 02/05/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202444763
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $16,233.75 02/05/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274887
Principal investigator 1 Janssen Research & Development, LLC $2,288.00 01/27/2025 Non-covered Recipient Entity
Modern Rsrch Associates Pllc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175278430
Principal investigator 1 PFIZER INC. $4,342.80 01/24/2025 Non-covered Recipient Entity
Modern Research Associates PLLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228801511
Principal investigator 1 SANOFI US SERVICES INC. $3,212.40 01/21/2025 Non-covered Recipient Entity
Modern Research Associates Plc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226133144
Principal investigator 1 Janssen Research & Development, LLC $6,122.00 01/16/2025 Non-covered Recipient Entity
Modern Rsrch Associates Pllc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175280427
Principal investigator 1 Eli Lilly and Company $58,717.00 01/08/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1187885040
Principal investigator 1 ABBVIE INC. $1,935.01 01/02/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202436255
Principal investigator 1 ABBVIE INC. $3,695.00 01/02/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202436259
Principal investigator 1 ABBVIE INC. $3,365.00 01/02/2025 Non-covered Recipient Entity
MODERN RESEARCH ASSOCIATES PLLC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202436263